Average Co-Inventor Count = 3.68
ph-index = 9
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Northwest Biotherapeutics, Inc. (9 from 16 patents)
2. Medarex Inc. (4 from 152 patents)
3. Pacific Northwest Cancer Foundation (2 from 2 patents)
4. Northwest Hospital (1 from 3 patents)
5. Gerald P. Murphy Cancer Foundation (1 from 1 patent)
17 patents:
1. 9566294 - Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
2. 8518636 - Tangential flow filtration devices and methods for leukocyte enrichment
3. 8409566 - Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
4. 7790039 - Tangential flow filtration devices and methods for stem cell enrichment
5. 7695627 - Tangential flow filtration devices and methods for leukocyte enrichment
6. 7476513 - Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen
7. 7381407 - Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
8. 7201900 - Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
9. 7160868 - [object Object]
10. 6962981 - Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
11. 6863887 - Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
12. 6383759 - Non-invasive method to detect prostate cancer
13. 6200765 - Non-invasive methods to detect prostate cancer
14. 6150508 - Monoclonal antibodies specific for the extracellular domain of
15. 5990294 - Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene,